Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.

Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, Oyebadejo TY, Banjo AA, Deji-Agboola AM, Rakha EA, Green AR, Ellis IO.

Breast Cancer Res Treat. 2012 Sep;135(2):555-69. doi: 10.1007/s10549-012-2173-7. Epub 2012 Jul 29.

PMID:
22842985
2.

Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.

Agboola AO, Banjo AA, Anunobi CC, Ayoade BA, Deji-Agboola AM, Musa AA, Abdel-Fatah T, Nolan CC, Rakha EA, Ellis IO, Green AR.

Malays J Pathol. 2014 Apr;36(1):3-17.

3.

PIASĪ³ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.

Agboola A, Musa A, Banjo A, Ayoade B, Deji-Agboola M, Nolan C, Rakha E, Ellis I, Green A.

J Clin Pathol. 2014 Apr;67(4):301-6. doi: 10.1136/jclinpath-2013-201658. Epub 2013 Oct 29.

PMID:
24170211
4.

Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.

Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BA, Rakha EA, Nolan CC, Ellis IO, Green AR.

Pathol Res Pract. 2017 Jan;213(1):27-33. doi: 10.1016/j.prp.2016.10.005. Epub 2016 Oct 25.

PMID:
27914769
5.

Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.

Agboola AO, Musa AA, Ayoade BA, Banjo AA, Anunobi CC, Deji-Agboola AM, Rakha EA, Nolan C, Ellis IO, Green AR.

Pathol Res Pract. 2014 Jan;210(1):10-7. doi: 10.1016/j.prp.2013.09.011. Epub 2013 Oct 8.

PMID:
24176171
6.

The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients.

Khoshnaw SM, Rakha EA, Abdel-Fatah T, Nolan CC, Hodi Z, Macmillan RD, Ellis IO, Green AR.

Breast Cancer Res Treat. 2013 Jan;137(1):139-53. doi: 10.1007/s10549-012-2358-0. Epub 2012 Dec 6.

PMID:
23225145
7.

US breast cancer mortality trends in young women according to race.

Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ.

Cancer. 2015 May 1;121(9):1469-76. doi: 10.1002/cncr.29178. Epub 2014 Dec 5.

8.

Loss of Dicer expression is associated with breast cancer progression and recurrence.

Khoshnaw SM, Rakha EA, Abdel-Fatah TM, Nolan CC, Hodi Z, Macmillan DR, Ellis IO, Green AR.

Breast Cancer Res Treat. 2012 Sep;135(2):403-13. doi: 10.1007/s10549-012-2169-3. Epub 2012 Jul 21.

PMID:
22821364
9.

Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer.

Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green AR, Ali S, Rakha EA, Ellis IO.

Breast Cancer Res Treat. 2015 Apr;150(2):335-46. doi: 10.1007/s10549-015-3335-1. Epub 2015 Mar 12.

PMID:
25762479
10.

Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women.

Agboola AO, Banjo AA, Anunobi CC, Salami B, Agboola MD, Musa AA, Nolan CC, Rakha EA, Ellis IO, Green AR.

ISRN Oncol. 2013 Apr 11;2013:675051. doi: 10.1155/2013/675051. Print 2013.

11.

Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.

Titloye NA, Foster A, Omoniyi-Esan GO, Komolafe AO, Daramola AO, Adeoye OA, Adisa AO, Manoharan A, Pathak D, D'Cruz MN, Alizadeh Y, Lewis PD, Shaaban AM.

Pathobiology. 2016;83(1):24-32. doi: 10.1159/000441949. Epub 2016 Jan 6.

PMID:
26730581
12.

Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer.

Tan F, Mosunjac M, Adams AL, Adade B, Taye O, Hu Y, Rizzo M, Ofori-Acquah SF.

BMC Cancer. 2014 Sep 25;14:715. doi: 10.1186/1471-2407-14-715.

13.
14.

Expression of BRCA1 protein in breast cancer and its prognostic significance.

Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO.

Hum Pathol. 2008 Jun;39(6):857-65. doi: 10.1016/j.humpath.2007.10.011. Epub 2008 Apr 8.

PMID:
18400253
15.

Lack of expression of the proteins GMPR2 and PPARĪ± are associated with the basal phenotype and patient outcome in breast cancer.

Baker BG, Ball GR, Rakha EA, Nolan CC, Caldas C, Ellis IO, Green AR.

Breast Cancer Res Treat. 2013 Jan;137(1):127-37. doi: 10.1007/s10549-012-2302-3. Epub 2012 Dec 4.

PMID:
23208589
16.

Calpain system protein expression in basal-like and triple-negative invasive breast cancer.

Storr SJ, Lee KW, Woolston CM, Safuan S, Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO, Martin SG.

Ann Oncol. 2012 Sep;23(9):2289-96. doi: 10.1093/annonc/mds176. Epub 2012 Jun 27.

17.

Early onset of breast cancer in a group of British black women.

Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL.

Br J Cancer. 2008 Jan 29;98(2):277-81. doi: 10.1038/sj.bjc.6604174. Epub 2008 Jan 8.

18.

Prognostic and biological significance of microRNA-127 expression in human breast cancer.

Wang S, Li H, Wang J, Wang D, Yao A, Li Q.

Dis Markers. 2014;2014:401986. doi: 10.1155/2014/401986. Epub 2014 Nov 12.

19.

Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.

Cao AY, He M, Liu ZB, Di GH, Wu J, Lu JS, Liu GY, Shen ZZ, Shao ZM.

Ann Surg Oncol. 2012 Sep;19(9):3019-27. doi: 10.1245/s10434-012-2322-6. Epub 2012 Mar 27.

PMID:
22451233
20.

Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO.

J Pathol. 2006 Mar;208(4):495-506.

PMID:
16429394

Supplemental Content

Support Center